A global PE company with dedicated Life Science investment funds is looking to provide seed, venture and growth capital to companies in the life science space.  The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise.  The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based fund seeks to provide debt financing to companies in the life science and healthcare sectors; financing is offered in the forms of senior secured term loans, cash flow loans, revolving lines of credit, real estate and equipment loans. Loans may vary in size from $500,000 to $50m, with ranges and payment terms varying according to the type of loan provided. The firm typically issues about $400-500m in debt per year. Debt is provided to companies for working capital, growth, expansions, recapitalizations, product licensing or acquisitions, or to purchase equipment or real estate. The firm considers opportunities in the USA, Canada, Europe and Oceania.

In the life science sector, the firm is most interested in companies developing therapeutics and medical devices. The firm considers lending to therapeutic companies with a product in Phase I development or later, or to device companies in clinical development or later.

The firm provides capital to both revenue generating and pre-revenue companies. Typically, capital is deployed to bring a company to the next inflection point (such as break-even or an acquisition). The firm prefers to lend to companies that have already received the backing of a number of institutional investors such as VCs.  The ability of these investors to provide follow-on financing, if necessary, is a key part of the evaluation of an opportunity. When considering management teams, the firm prefers those who have prior industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based private equity firm founded in 2000 is actively investing from two funds. The firm currently has $150M in AUM. The group typically invests from $8M – 20M over the lifetime of an investment and anticipates investments in 2 – 3 platforms over the next year. Investments in the United States and Canada are of interest.

The firm primarily considers medical devices and diagnostics that overlap with or contribute to the healthcare IT and service landscapes, where they predominantly invest. The firm will consider all classes of medical devices. The group is agnostic in terms of indication.

The firm seeks a board seat and is extremely involved in management of portfolio companies. The group seeks a strong management team that has scaled a company in the past. The group prefers to leads investments but will consider co-investing. Growth-stage companies with products already on the market are the core focus of the firm. Though the firm prefers a positive cash flow, it will consider companies not yet making a profit, if the company has a controlled burn rate. The group will also consider add-on devices not yet on the market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global VC based in California is investing from its latest, which closed at over 2 billion in 2012.  The firm invests broadly in the healthcare and technology sectors, and while investments are made at seed, venture and growth stages of development, the firm primarily invests in Series A rounds.  The firm makes investments globally, and as the sizes of allocations are highly varied.

Within healthcare, the firm focuses on biopharma, medical devices, healthcare IT and healthcare service providers (including providers of diagnostic services).  The firm is open to investing in any indication area, including orphan diseases, and the firm will consider opportunities as early as preclinical development.  Within the healthcare IT sector, the firm’s expertise is primarily with companies that provide IT products and services to healthcare providers; Life science software companies, including connected devices and lab software, are also of interest.

The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life sciences-focused venture capital incubator/accelerator based on the east coast seeks to provide capital in the form of equity and convertible notes to seed and venture stage companies. The firm can provide capital in the range of a few hundred thousand to $2 million or more by leveraging its groups of angel syndicates. The firm invests in companies across the United States, Europe and Australia with a preference for California based companies. The firm looks to be involved in 3 new companies per year.

The firm is currently looking for companies in areas of medical technology/devices, therapeutics and companion diagnostics. In the medical device space the firm is open in terms of sector and indication and will consider firms that are in the development phase as well as those that have entered clinical trials. In the therapeutics space the firm is generally open as well however the firm is highly interested in areas of cell and gene therapy and oncology. For therapeutics the firm tends to get involved at the preclinical stage or during phase I of clinical trials.

The firm requires confident and experienced management teams. Given the early stage investment style that the firm has, they often work with management teams that are incomplete and have primarily academic backgrounds. Part of the value that the investor seeks to add is helping firms fill in the gaps in their current management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Connecticut seeks to provide growth capital to life science companies. The group invests up to $10M in equity, venture debt, or traditional mezzanine. The fund prefers VC backed companies. Funding opportunities are reserved for companies in or willing to relocate to Connecticut.

The group prefers products with a short regulatory pathway, with a preference for medical devices. The firm typically avoids pure drug discovery, unless the product has an expedited regulatory pathway or is in later stages of approval. For medical devices, the group seeks technology with market traction. This includes companies with sales or a product in use by thought leaders.

The firm is willing to lead investments but prefers to act as a co-investor. The group invests in companies with established technology and a strong management team with deep domain experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture and growth capital firm seeks to provide expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm is based in Switzerland and focuses on early to growth and expansion stage (including spin-offs and restarts). The firm expects to close its new medical technology fund in the summer of 2014. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate $2-10M (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in therapeutic medical devices, diagnostics and monitoring, and digital health. The firm is opportunistic in terms of subsectors and indications. The firm prefers products that are close to or with market approval. At minimum, the product must have clinical data. The firm will consider companies that are generating revenue. Historically, the firm invested in molecular diagnostics, implantable devices for pulmonary and cardiovascular diseases, delivery and single-use devices for metabolic disorders, and dental device.

Typically, the firm requests a board seat in each portfolio company and generally holds a stake of 10-30 percent. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com